+1 (704) 266-3234
+1 (704) 266-3234You are here :
Published on: Jan 2024 | From USD $3660 | Published By: LP INFORMATION INC | Number Of Pages: 121
According to our LPI (LP Information) latest study, the global PD-1 and PD-L1 Inhibitors market size was valued at US$ 38690 million in 2023. With growing demand in downstream market, the PD-1 and PD-L1 Inhibitors is forecast to a readjusted size of US$ 146540 million by 2030 with a CAGR of 21.0% during review period.
The research report highlights the growth potential of the global PD-1 and PD-L1 Inhibitors market. PD-1 and PD-L1 Inhibitors are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of PD-1 and PD-L1 Inhibitors. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the PD-1 and PD-L1 Inhibitors market.
PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer.
North America is the largest consumption place, with a consumption market share nearly 60.40% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 20.66%.Market competition is intense. Merck, Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical etc. are the leaders of the industry.
Key Features:
The report on PD-1 and PD-L1 Inhibitors market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the PD-1 and PD-L1 Inhibitors market. It may include historical data, market segmentation by Type (e.g., PD-1 Inhibitors, PD-L1 Inhibitors), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the PD-1 and PD-L1 Inhibitors market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the PD-1 and PD-L1 Inhibitors market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the PD-1 and PD-L1 Inhibitors industry. This include advancements in PD-1 and PD-L1 Inhibitors technology, PD-1 and PD-L1 Inhibitors new entrants, PD-1 and PD-L1 Inhibitors new investment, and other innovations that are shaping the future of PD-1 and PD-L1 Inhibitors.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the PD-1 and PD-L1 Inhibitors market. It includes factors influencing customer ' purchasing decisions, preferences for PD-1 and PD-L1 Inhibitors product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the PD-1 and PD-L1 Inhibitors market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting PD-1 and PD-L1 Inhibitors market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the PD-1 and PD-L1 Inhibitors market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the PD-1 and PD-L1 Inhibitors industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the PD-1 and PD-L1 Inhibitors market.
Market Segmentation:
PD-1 and PD-L1 Inhibitors market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
PD-1 Inhibitors
PD-L1 Inhibitors
Segmentation by application
Solid Tumors
Blood-related Tumors
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck
Bristol-Myers Squibb
Roche
AstraZeneca
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
Merck KGaA
Key Questions Addressed in this Report
What is the 10-year outlook for the global PD-1 and PD-L1 Inhibitors market?
What factors are driving PD-1 and PD-L1 Inhibitors market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do PD-1 and PD-L1 Inhibitors market opportunities vary by end market size?
How does PD-1 and PD-L1 Inhibitors break out type, application?
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global PD-1 and PD-L1 Inhibitors Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Country/Region, 2019, 2023 & 2030
2.2 PD-1 and PD-L1 Inhibitors Segment by Type
2.2.1 PD-1 Inhibitors
2.2.2 PD-L1 Inhibitors
2.3 PD-1 and PD-L1 Inhibitors Sales by Type
2.3.1 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2019-2024)
2.3.2 Global PD-1 and PD-L1 Inhibitors Revenue and Market Share by Type (2019-2024)
2.3.3 Global PD-1 and PD-L1 Inhibitors Sale Price by Type (2019-2024)
2.4 PD-1 and PD-L1 Inhibitors Segment by Application
2.4.1 Solid Tumors
2.4.2 Blood-related Tumors
2.5 PD-1 and PD-L1 Inhibitors Sales by Application
2.5.1 Global PD-1 and PD-L1 Inhibitors Sale Market Share by Application (2019-2024)
2.5.2 Global PD-1 and PD-L1 Inhibitors Revenue and Market Share by Application (2019-2024)
2.5.3 Global PD-1 and PD-L1 Inhibitors Sale Price by Application (2019-2024)
3 Global PD-1 and PD-L1 Inhibitors by Company
3.1 Global PD-1 and PD-L1 Inhibitors Breakdown Data by Company
3.1.1 Global PD-1 and PD-L1 Inhibitors Annual Sales by Company (2019-2024)
3.1.2 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Company (2019-2024)
3.2 Global PD-1 and PD-L1 Inhibitors Annual Revenue by Company (2019-2024)
3.2.1 Global PD-1 and PD-L1 Inhibitors Revenue by Company (2019-2024)
3.2.2 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Company (2019-2024)
3.3 Global PD-1 and PD-L1 Inhibitors Sale Price by Company
3.4 Key Manufacturers PD-1 and PD-L1 Inhibitors Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers PD-1 and PD-L1 Inhibitors Product Location Distribution
3.4.2 Players PD-1 and PD-L1 Inhibitors Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for PD-1 and PD-L1 Inhibitors by Geographic Region
4.1 World Historic PD-1 and PD-L1 Inhibitors Market Size by Geographic Region (2019-2024)
4.1.1 Global PD-1 and PD-L1 Inhibitors Annual Sales by Geographic Region (2019-2024)
4.1.2 Global PD-1 and PD-L1 Inhibitors Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic PD-1 and PD-L1 Inhibitors Market Size by Country/Region (2019-2024)
4.2.1 Global PD-1 and PD-L1 Inhibitors Annual Sales by Country/Region (2019-2024)
4.2.2 Global PD-1 and PD-L1 Inhibitors Annual Revenue by Country/Region (2019-2024)
4.3 Americas PD-1 and PD-L1 Inhibitors Sales Growth
4.4 APAC PD-1 and PD-L1 Inhibitors Sales Growth
4.5 Europe PD-1 and PD-L1 Inhibitors Sales Growth
4.6 Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Growth
5 Americas
5.1 Americas PD-1 and PD-L1 Inhibitors Sales by Country
5.1.1 Americas PD-1 and PD-L1 Inhibitors Sales by Country (2019-2024)
5.1.2 Americas PD-1 and PD-L1 Inhibitors Revenue by Country (2019-2024)
5.2 Americas PD-1 and PD-L1 Inhibitors Sales by Type
5.3 Americas PD-1 and PD-L1 Inhibitors Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC PD-1 and PD-L1 Inhibitors Sales by Region
6.1.1 APAC PD-1 and PD-L1 Inhibitors Sales by Region (2019-2024)
6.1.2 APAC PD-1 and PD-L1 Inhibitors Revenue by Region (2019-2024)
6.2 APAC PD-1 and PD-L1 Inhibitors Sales by Type
6.3 APAC PD-1 and PD-L1 Inhibitors Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe PD-1 and PD-L1 Inhibitors by Country
7.1.1 Europe PD-1 and PD-L1 Inhibitors Sales by Country (2019-2024)
7.1.2 Europe PD-1 and PD-L1 Inhibitors Revenue by Country (2019-2024)
7.2 Europe PD-1 and PD-L1 Inhibitors Sales by Type
7.3 Europe PD-1 and PD-L1 Inhibitors Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa PD-1 and PD-L1 Inhibitors by Country
8.1.1 Middle East & Africa PD-1 and PD-L1 Inhibitors Sales by Country (2019-2024)
8.1.2 Middle East & Africa PD-1 and PD-L1 Inhibitors Revenue by Country (2019-2024)
8.2 Middle East & Africa PD-1 and PD-L1 Inhibitors Sales by Type
8.3 Middle East & Africa PD-1 and PD-L1 Inhibitors Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of PD-1 and PD-L1 Inhibitors
10.3 Manufacturing Process Analysis of PD-1 and PD-L1 Inhibitors
10.4 Industry Chain Structure of PD-1 and PD-L1 Inhibitors
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 PD-1 and PD-L1 Inhibitors Distributors
11.3 PD-1 and PD-L1 Inhibitors Customer
12 World Forecast Review for PD-1 and PD-L1 Inhibitors by Geographic Region
12.1 Global PD-1 and PD-L1 Inhibitors Market Size Forecast by Region
12.1.1 Global PD-1 and PD-L1 Inhibitors Forecast by Region (2025-2030)
12.1.2 Global PD-1 and PD-L1 Inhibitors Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global PD-1 and PD-L1 Inhibitors Forecast by Type
12.7 Global PD-1 and PD-L1 Inhibitors Forecast by Application
13 Key Players Analysis
13.1 Merck
13.1.1 Merck Company Information
13.1.2 Merck PD-1 and PD-L1 Inhibitors Product Portfolios and Specifications
13.1.3 Merck PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Merck Main Business Overview
13.1.5 Merck Latest Developments
13.2 Bristol-Myers Squibb
13.2.1 Bristol-Myers Squibb Company Information
13.2.2 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product Portfolios and Specifications
13.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Bristol-Myers Squibb Main Business Overview
13.2.5 Bristol-Myers Squibb Latest Developments
13.3 Roche
13.3.1 Roche Company Information
13.3.2 Roche PD-1 and PD-L1 Inhibitors Product Portfolios and Specifications
13.3.3 Roche PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Roche Main Business Overview
13.3.5 Roche Latest Developments
13.4 AstraZeneca
13.4.1 AstraZeneca Company Information
13.4.2 AstraZeneca PD-1 and PD-L1 Inhibitors Product Portfolios and Specifications
13.4.3 AstraZeneca PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 AstraZeneca Main Business Overview
13.4.5 AstraZeneca Latest Developments
13.5 Ono Pharmaceutical
13.5.1 Ono Pharmaceutical Company Information
13.5.2 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Product Portfolios and Specifications
13.5.3 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Ono Pharmaceutical Main Business Overview
13.5.5 Ono Pharmaceutical Latest Developments
13.6 Regeneron
13.6.1 Regeneron Company Information
13.6.2 Regeneron PD-1 and PD-L1 Inhibitors Product Portfolios and Specifications
13.6.3 Regeneron PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Regeneron Main Business Overview
13.6.5 Regeneron Latest Developments
13.7 Innovent
13.7.1 Innovent Company Information
13.7.2 Innovent PD-1 and PD-L1 Inhibitors Product Portfolios and Specifications
13.7.3 Innovent PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Innovent Main Business Overview
13.7.5 Innovent Latest Developments
13.8 Hengrui Medicine
13.8.1 Hengrui Medicine Company Information
13.8.2 Hengrui Medicine PD-1 and PD-L1 Inhibitors Product Portfolios and Specifications
13.8.3 Hengrui Medicine PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Hengrui Medicine Main Business Overview
13.8.5 Hengrui Medicine Latest Developments
13.9 Junshi Biosciences
13.9.1 Junshi Biosciences Company Information
13.9.2 Junshi Biosciences PD-1 and PD-L1 Inhibitors Product Portfolios and Specifications
13.9.3 Junshi Biosciences PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Junshi Biosciences Main Business Overview
13.9.5 Junshi Biosciences Latest Developments
13.10 Merck KGaA
13.10.1 Merck KGaA Company Information
13.10.2 Merck KGaA PD-1 and PD-L1 Inhibitors Product Portfolios and Specifications
13.10.3 Merck KGaA PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Merck KGaA Main Business Overview
13.10.5 Merck KGaA Latest Developments
14 Research Findings and Conclusion
List of Tables
Table 1. PD-1 and PD-L1 Inhibitors Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. PD-1 and PD-L1 Inhibitors Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of PD-1 Inhibitors
Table 4. Major Players of PD-L1 Inhibitors
Table 5. Global PD-1 and PD-L1 Inhibitors Sales by Type (2019-2024) & (L)
Table 6. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2019-2024)
Table 7. Global PD-1 and PD-L1 Inhibitors Revenue by Type (2019-2024) & ($ million)
Table 8. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2019-2024)
Table 9. Global PD-1 and PD-L1 Inhibitors Sale Price by Type (2019-2024) & (USD/ml)
Table 10. Global PD-1 and PD-L1 Inhibitors Sales by Application (2019-2024) & (L)
Table 11. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2019-2024)
Table 12. Global PD-1 and PD-L1 Inhibitors Revenue by Application (2019-2024)
Table 13. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2019-2024)
Table 14. Global PD-1 and PD-L1 Inhibitors Sale Price by Application (2019-2024) & (USD/ml)
Table 15. Global PD-1 and PD-L1 Inhibitors Sales by Company (2019-2024) & (L)
Table 16. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Company (2019-2024)
Table 17. Global PD-1 and PD-L1 Inhibitors Revenue by Company (2019-2024) ($ Millions)
Table 18. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Company (2019-2024)
Table 19. Global PD-1 and PD-L1 Inhibitors Sale Price by Company (2019-2024) & (USD/ml)
Table 20. Key Manufacturers PD-1 and PD-L1 Inhibitors Producing Area Distribution and Sales Area
Table 21. Players PD-1 and PD-L1 Inhibitors Products Offered
Table 22. PD-1 and PD-L1 Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global PD-1 and PD-L1 Inhibitors Sales by Geographic Region (2019-2024) & (L)
Table 26. Global PD-1 and PD-L1 Inhibitors Sales Market Share Geographic Region (2019-2024)
Table 27. Global PD-1 and PD-L1 Inhibitors Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global PD-1 and PD-L1 Inhibitors Sales by Country/Region (2019-2024) & (L)
Table 30. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Country/Region (2019-2024)
Table 31. Global PD-1 and PD-L1 Inhibitors Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas PD-1 and PD-L1 Inhibitors Sales by Country (2019-2024) & (L)
Table 34. Americas PD-1 and PD-L1 Inhibitors Sales Market Share by Country (2019-2024)
Table 35. Americas PD-1 and PD-L1 Inhibitors Revenue by Country (2019-2024) & ($ Millions)
Table 36. Americas PD-1 and PD-L1 Inhibitors Revenue Market Share by Country (2019-2024)
Table 37. Americas PD-1 and PD-L1 Inhibitors Sales by Type (2019-2024) & (L)
Table 38. Americas PD-1 and PD-L1 Inhibitors Sales by Application (2019-2024) & (L)
Table 39. APAC PD-1 and PD-L1 Inhibitors Sales by Region (2019-2024) & (L)
Table 40. APAC PD-1 and PD-L1 Inhibitors Sales Market Share by Region (2019-2024)
Table 41. APAC PD-1 and PD-L1 Inhibitors Revenue by Region (2019-2024) & ($ Millions)
Table 42. APAC PD-1 and PD-L1 Inhibitors Revenue Market Share by Region (2019-2024)
Table 43. APAC PD-1 and PD-L1 Inhibitors Sales by Type (2019-2024) & (L)
Table 44. APAC PD-1 and PD-L1 Inhibitors Sales by Application (2019-2024) & (L)
Table 45. Europe PD-1 and PD-L1 Inhibitors Sales by Country (2019-2024) & (L)
Table 46. Europe PD-1 and PD-L1 Inhibitors Sales Market Share by Country (2019-2024)
Table 47. Europe PD-1 and PD-L1 Inhibitors Revenue by Country (2019-2024) & ($ Millions)
Table 48. Europe PD-1 and PD-L1 Inhibitors Revenue Market Share by Country (2019-2024)
Table 49. Europe PD-1 and PD-L1 Inhibitors Sales by Type (2019-2024) & (L)
Table 50. Europe PD-1 and PD-L1 Inhibitors Sales by Application (2019-2024) & (L)
Table 51. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales by Country (2019-2024) & (L)
Table 52. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Market Share by Country (2019-2024)
Table 53. Middle East & Africa PD-1 and PD-L1 Inhibitors Revenue by Country (2019-2024) & ($ Millions)
Table 54. Middle East & Africa PD-1 and PD-L1 Inhibitors Revenue Market Share by Country (2019-2024)
Table 55. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales by Type (2019-2024) & (L)
Table 56. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales by Application (2019-2024) & (L)
Table 57. Key Market Drivers & Growth Opportunities of PD-1 and PD-L1 Inhibitors
Table 58. Key Market Challenges & Risks of PD-1 and PD-L1 Inhibitors
Table 59. Key Industry Trends of PD-1 and PD-L1 Inhibitors
Table 60. PD-1 and PD-L1 Inhibitors Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. PD-1 and PD-L1 Inhibitors Distributors List
Table 63. PD-1 and PD-L1 Inhibitors Customer List
Table 64. Global PD-1 and PD-L1 Inhibitors Sales Forecast by Region (2025-2030) & (L)
Table 65. Global PD-1 and PD-L1 Inhibitors Revenue Forecast by Region (2025-2030) & ($ millions)
Table 66. Americas PD-1 and PD-L1 Inhibitors Sales Forecast by Country (2025-2030) & (L)
Table 67. Americas PD-1 and PD-L1 Inhibitors Revenue Forecast by Country (2025-2030) & ($ millions)
Table 68. APAC PD-1 and PD-L1 Inhibitors Sales Forecast by Region (2025-2030) & (L)
Table 69. APAC PD-1 and PD-L1 Inhibitors Revenue Forecast by Region (2025-2030) & ($ millions)
Table 70. Europe PD-1 and PD-L1 Inhibitors Sales Forecast by Country (2025-2030) & (L)
Table 71. Europe PD-1 and PD-L1 Inhibitors Revenue Forecast by Country (2025-2030) & ($ millions)
Table 72. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Forecast by Country (2025-2030) & (L)
Table 73. Middle East & Africa PD-1 and PD-L1 Inhibitors Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Global PD-1 and PD-L1 Inhibitors Sales Forecast by Type (2025-2030) & (L)
Table 75. Global PD-1 and PD-L1 Inhibitors Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 76. Global PD-1 and PD-L1 Inhibitors Sales Forecast by Application (2025-2030) & (L)
Table 77. Global PD-1 and PD-L1 Inhibitors Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 78. Merck Basic Information, PD-1 and PD-L1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 79. Merck PD-1 and PD-L1 Inhibitors Product Portfolios and Specifications
Table 80. Merck PD-1 and PD-L1 Inhibitors Sales (L), Revenue ($ Million), Price (USD/ml) and Gross Margin (2019-2024)
Table 81. Merck Main Business
Table 82. Merck Latest Developments
Table 83. Bristol-Myers Squibb Basic Information, PD-1 and PD-L1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 84. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product Portfolios and Specifications
Table 85. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Sales (L), Revenue ($ Million), Price (USD/ml) and Gross Margin (2019-2024)
Table 86. Bristol-Myers Squibb Main Business
Table 87. Bristol-Myers Squibb Latest Developments
Table 88. Roche Basic Information, PD-1 and PD-L1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 89. Roche PD-1 and PD-L1 Inhibitors Product Portfolios and Specifications
Table 90. Roche PD-1 and PD-L1 Inhibitors Sales (L), Revenue ($ Million), Price (USD/ml) and Gross Margin (2019-2024)
Table 91. Roche Main Business
Table 92. Roche Latest Developments
Table 93. AstraZeneca Basic Information, PD-1 and PD-L1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 94. AstraZeneca PD-1 and PD-L1 Inhibitors Product Portfolios and Specifications
Table 95. AstraZeneca PD-1 and PD-L1 Inhibitors Sales (L), Revenue ($ Million), Price (USD/ml) and Gross Margin (2019-2024)
Table 96. AstraZeneca Main Business
Table 97. AstraZeneca Latest Developments
Table 98. Ono Pharmaceutical Basic Information, PD-1 and PD-L1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 99. Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Product Portfolios and Specifications
Table 100. Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Sales (L), Revenue ($ Million), Price (USD/ml) and Gross Margin (2019-2024)
Table 101. Ono Pharmaceutical Main Business
Table 102. Ono Pharmaceutical Latest Developments
Table 103. Regeneron Basic Information, PD-1 and PD-L1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 104. Regeneron PD-1 and PD-L1 Inhibitors Product Portfolios and Specifications
Table 105. Regeneron PD-1 and PD-L1 Inhibitors Sales (L), Revenue ($ Million), Price (USD/ml) and Gross Margin (2019-2024)
Table 106. Regeneron Main Business
Table 107. Regeneron Latest Developments
Table 108. Innovent Basic Information, PD-1 and PD-L1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 109. Innovent PD-1 and PD-L1 Inhibitors Product Portfolios and Specifications
Table 110. Innovent PD-1 and PD-L1 Inhibitors Sales (L), Revenue ($ Million), Price (USD/ml) and Gross Margin (2019-2024)
Table 111. Innovent Main Business
Table 112. Innovent Latest Developments
Table 113. Hengrui Medicine Basic Information, PD-1 and PD-L1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 114. Hengrui Medicine PD-1 and PD-L1 Inhibitors Product Portfolios and Specifications
Table 115. Hengrui Medicine PD-1 and PD-L1 Inhibitors Sales (L), Revenue ($ Million), Price (USD/ml) and Gross Margin (2019-2024)
Table 116. Hengrui Medicine Main Business
Table 117. Hengrui Medicine Latest Developments
Table 118. Junshi Biosciences Basic Information, PD-1 and PD-L1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 119. Junshi Biosciences PD-1 and PD-L1 Inhibitors Product Portfolios and Specifications
Table 120. Junshi Biosciences PD-1 and PD-L1 Inhibitors Sales (L), Revenue ($ Million), Price (USD/ml) and Gross Margin (2019-2024)
Table 121. Junshi Biosciences Main Business
Table 122. Junshi Biosciences Latest Developments
Table 123. Merck KGaA Basic Information, PD-1 and PD-L1 Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 124. Merck KGaA PD-1 and PD-L1 Inhibitors Product Portfolios and Specifications
Table 125. Merck KGaA PD-1 and PD-L1 Inhibitors Sales (L), Revenue ($ Million), Price (USD/ml) and Gross Margin (2019-2024)
Table 126. Merck KGaA Main Business
Table 127. Merck KGaA Latest Developments
List of Figures
Figure 1. Picture of PD-1 and PD-L1 Inhibitors
Figure 2. PD-1 and PD-L1 Inhibitors Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global PD-1 and PD-L1 Inhibitors Sales Growth Rate 2019-2030 (L)
Figure 7. Global PD-1 and PD-L1 Inhibitors Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. PD-1 and PD-L1 Inhibitors Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of PD-1 Inhibitors
Figure 10. Product Picture of PD-L1 Inhibitors
Figure 11. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type in 2023
Figure 12. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2019-2024)
Figure 13. PD-1 and PD-L1 Inhibitors Consumed in Solid Tumors
Figure 14. Global PD-1 and PD-L1 Inhibitors Market: Solid Tumors (2019-2024) & (L)
Figure 15. PD-1 and PD-L1 Inhibitors Consumed in Blood-related Tumors
Figure 16. Global PD-1 and PD-L1 Inhibitors Market: Blood-related Tumors (2019-2024) & (L)
Figure 17. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2023)
Figure 18. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application in 2023
Figure 19. PD-1 and PD-L1 Inhibitors Sales Market by Company in 2023 (L)
Figure 20. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Company in 2023
Figure 21. PD-1 and PD-L1 Inhibitors Revenue Market by Company in 2023 ($ Million)
Figure 22. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Company in 2023
Figure 23. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Geographic Region (2019-2024)
Figure 24. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Geographic Region in 2023
Figure 25. Americas PD-1 and PD-L1 Inhibitors Sales 2019-2024 (L)
Figure 26. Americas PD-1 and PD-L1 Inhibitors Revenue 2019-2024 ($ Millions)
Figure 27. APAC PD-1 and PD-L1 Inhibitors Sales 2019-2024 (L)
Figure 28. APAC PD-1 and PD-L1 Inhibitors Revenue 2019-2024 ($ Millions)
Figure 29. Europe PD-1 and PD-L1 Inhibitors Sales 2019-2024 (L)
Figure 30. Europe PD-1 and PD-L1 Inhibitors Revenue 2019-2024 ($ Millions)
Figure 31. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales 2019-2024 (L)
Figure 32. Middle East & Africa PD-1 and PD-L1 Inhibitors Revenue 2019-2024 ($ Millions)
Figure 33. Americas PD-1 and PD-L1 Inhibitors Sales Market Share by Country in 2023
Figure 34. Americas PD-1 and PD-L1 Inhibitors Revenue Market Share by Country in 2023
Figure 35. Americas PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2019-2024)
Figure 36. Americas PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2019-2024)
Figure 37. United States PD-1 and PD-L1 Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 38. Canada PD-1 and PD-L1 Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 39. Mexico PD-1 and PD-L1 Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 40. Brazil PD-1 and PD-L1 Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 41. APAC PD-1 and PD-L1 Inhibitors Sales Market Share by Region in 2023
Figure 42. APAC PD-1 and PD-L1 Inhibitors Revenue Market Share by Regions in 2023
Figure 43. APAC PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2019-2024)
Figure 44. APAC PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2019-2024)
Figure 45. China PD-1 and PD-L1 Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 46. Japan PD-1 and PD-L1 Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 47. South Korea PD-1 and PD-L1 Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 48. Southeast Asia PD-1 and PD-L1 Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 49. India PD-1 and PD-L1 Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 50. Australia PD-1 and PD-L1 Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 51. China Taiwan PD-1 and PD-L1 Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 52. Europe PD-1 and PD-L1 Inhibitors Sales Market Share by Country in 2023
Figure 53. Europe PD-1 and PD-L1 Inhibitors Revenue Market Share by Country in 2023
Figure 54. Europe PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2019-2024)
Figure 55. Europe PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2019-2024)
Figure 56. Germany PD-1 and PD-L1 Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 57. France PD-1 and PD-L1 Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 58. UK PD-1 and PD-L1 Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 59. Italy PD-1 and PD-L1 Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 60. Russia PD-1 and PD-L1 Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 61. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Market Share by Country in 2023
Figure 62. Middle East & Africa PD-1 and PD-L1 Inhibitors Revenue Market Share by Country in 2023
Figure 63. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2019-2024)
Figure 64. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2019-2024)
Figure 65. Egypt PD-1 and PD-L1 Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 66. South Africa PD-1 and PD-L1 Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 67. Israel PD-1 and PD-L1 Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 68. Turkey PD-1 and PD-L1 Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 69. GCC Country PD-1 and PD-L1 Inhibitors Revenue Growth 2019-2024 ($ Millions)
Figure 70. Manufacturing Cost Structure Analysis of PD-1 and PD-L1 Inhibitors in 2023
Figure 71. Manufacturing Process Analysis of PD-1 and PD-L1 Inhibitors
Figure 72. Industry Chain Structure of PD-1 and PD-L1 Inhibitors
Figure 73. Channels of Distribution
Figure 74. Global PD-1 and PD-L1 Inhibitors Sales Market Forecast by Region (2025-2030)
Figure 75. Global PD-1 and PD-L1 Inhibitors Revenue Market Share Forecast by Region (2025-2030)
Figure 76. Global PD-1 and PD-L1 Inhibitors Sales Market Share Forecast by Type (2025-2030)
Figure 77. Global PD-1 and PD-L1 Inhibitors Revenue Market Share Forecast by Type (2025-2030)
Figure 78. Global PD-1 and PD-L1 Inhibitors Sales Market Share Forecast by Application (2025-2030)
Figure 79. Global PD-1 and PD-L1 Inhibitors Revenue Market Share Forecast by Application (2025-2030)
SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.
In-depth database
Our Report’s database covers almost all topics of all regions over the Globe..
Recognised publishing sources
Tie ups with top publishers around the globe.
Customer Support
Complete pre and post sales support.
Safe & Secure
Complete secure payment process.
: sales@marketintelligencedata.com
: 1137 waynewood dr,Waxhaw NC 28173 ,United States
: +1 (704) 266-3234
